R. Eric Davis
Scripps MD Anderson Cancer Center(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research, Immune Cell Function and Interaction, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling(2000)9,905 cited
- → Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol(2001)372 cited
- → HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN‐LABEL, PHASE II STUDY(2017)12 cited
- → Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody(2012)1 cited
- → RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE AND COMBINED WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA(2017)1 cited
- → Building lymphochip-computational algorithms for selecting clones highly expressed in B cell cDNA libraries(1999)
- → Killing 2 birds with 1 stone in DLBCL(2021)
- Safety and Activity of Pembrolizumab in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma(2021)
- → VERY EARLY FDG PET/CT SCAN MAY PREDICT OUTCOMES IN RELAPSED OR REFRACTORY DLBCL PATIENTS TREATED WITH SALVAGE THERAPY(2019)
- → Analysis of gene expression in normal and malignant lymphocytes using the Lymphochip cDNA microarray(1999)